Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
Condition: Type2 Diabetes Interventions: Drug: Evogliptin 5mg; Drug: Evogliptin Placebo; Drug: Dapagliflozin 10mg; Drug: Metformin ≥ 1000mg Sponsor: Dong-A ST Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Forxiga | Metformin | Research